Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Product Development

June 5 Quick Takes: Merck, Tetraphase-Melinta, Apeiron, Neurasic, Jounce, Genmab-J&J

June 6, 2020 2:33 AM UTC

UCB buying Engage for $125M
UCB S.A. (Euronext:UCB) acquired Engage Therapeutics Inc. Friday, gaining Staccato alprazolam, a drug-inhaler combo in Phase II testing for the rapid termination of epileptic seizures. Engage will receive $125 million up front and is eligible for up to $145 million in milestones.

Expanded label for Merck’s Recarbrio
FDA approved Recarbrio relebactam/imipenem/cilastatin from Merck & Co. Inc. (NYSE:MRK) to treat hospital-acquired or ventilator-associated bacterial pneumonia in adults. The antibiotic combo is already approved for complicated intra-abdominal and urinary tract infections...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article